Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 387

1.

The Safety and Short-Term Outcomes of Leukocyte Depleted Autologous Transfusions during Radical Cystectomy.

Myrga JM, Ayyash OM, Bandari J, Fam MM, Macleod LC, Jacobs BL, Davies BJ.

Urology. 2019 Oct 15. pii: S0090-4295(19)30883-0. doi: 10.1016/j.urology.2019.08.056. [Epub ahead of print]

PMID:
31626857
2.

Correction for Kibler et al., "Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC".

Kibler KV, Asbach B, Perdiguero B, García-Arriaza J, Yates NL, Parks R, Stanfield-Oakley S, Ferrari G, Montefiori DC, Tomaras GD, Roederer M, Foulds KE, Forthal DN, Seaman MS, Self S, Gottardo R, Phogat S, Tartaglia J, Barnett S, Cristillo AD, Weiss D, Galmin L, Ding S, Heeney JL, Esteban M, Wagner R, Pantaleo G, Jacobs BL.

J Virol. 2019 Oct 15;93(21). pii: e00968-19. doi: 10.1128/JVI.00968-19. Print 2019 Nov 1. No abstract available.

3.

Editorial Comment.

Yu M, Davies BJ, Jacobs BL.

J Urol. 2019 Oct 3:10109701JU000060270444846e4. doi: 10.1097/01.JU.0000602704.44846.e4. [Epub ahead of print] No abstract available.

PMID:
31580767
4.

The Shrinking Grey Zone of Postoperative Narcotics in the Midst of the Opioid Crisis: The No-opioid Urologist.

Pekala KR, Jacobs BL, Davies BJ.

Eur Urol Focus. 2019 Sep 25. pii: S2405-4569(19)30272-X. doi: 10.1016/j.euf.2019.08.014. [Epub ahead of print]

PMID:
31563546
5.

Reversal of the Warburg phenomenon in chemoprevention of prostate cancer by sulforaphane.

Singh KB, Hahm ER, Alumkal JJ, Foley LM, Hitchens TK, Shiva SS, Parikh RA, Jacobs BL, Singh SV.

Carcinogenesis. 2019 Sep 26. pii: bgz155. doi: 10.1093/carcin/bgz155. [Epub ahead of print]

PMID:
31555797
6.

Implications of Cystectomy Travel Distance for Hospital Readmission and Survival.

Hale NE, Macleod LC, Yabes JG, Turner RM 2nd, Fam MM, Gingrich JR, Skolarus TA, Borza T, Sabik LM, Davies BJ, Jacobs BL.

Clin Genitourin Cancer. 2019 Aug 20. pii: S1558-7673(19)30254-X. doi: 10.1016/j.clgc.2019.08.005. [Epub ahead of print]

PMID:
31543443
7.

Undertreatment of Prostate Cancer in Rural Residents.

Maganty A, Sabik LM, Sun Z, Eom KY, Li J, Davies BJ, Jacobs BL.

J Urol. 2019 Aug 20:101097JU0000000000000500. doi: 10.1097/JU.0000000000000500. [Epub ahead of print]

PMID:
31430233
8.

The Influence of Stereotactic Body Radiation Therapy Adoption on Prostate Cancer Treatment Patterns.

Jacobs BL, Yabes JG, Lopa SH, Heron DE, Chang CH, Bekelman JE, Nelson JB, Bynum JPW, Barnato AE, Kahn JM.

J Urol. 2019 Jul 30:101097JU0000000000000471. doi: 10.1097/JU.0000000000000471. [Epub ahead of print]

PMID:
31361571
9.

Characterising 'bounce-back' readmissions after radical cystectomy.

Kirk PS, Skolarus TA, Jacobs BL, Qin Y, Li B, Sessine M, Liu X, Zhu K, Gilbert SM, Hollenbeck BK, Urish K, Helm J, Lavieri MS, Borza T.

BJU Int. 2019 Jul 17. doi: 10.1111/bju.14874. [Epub ahead of print]

PMID:
31313473
10.

Evaluation of the Risks and Benefits of Computed Tomography Urography for Assessment of Gross Hematuria.

Yecies T, Bandari J, Macleod L, Fam M, Davies BJ, Jacobs BL.

Urology. 2019 Jun 27. pii: S0090-4295(19)30596-5. doi: 10.1016/j.urology.2019.04.055. [Epub ahead of print]

PMID:
31255539
11.

E-cadherin is downregulated in benign prostatic hyperplasia and required for tight junction formation and permeability barrier in the prostatic epithelial cell monolayer.

Li F, Pascal LE, Stolz DB, Wang K, Zhou Y, Chen W, Xu Y, Chen Y, Dhir R, Parwani AV, Nelson JB, DeFranco DB, Yoshimura N, Balasubramani GK, Gingrich JR, Maranchie JK, Jacobs BL, Davies BJ, Hrebinko RL, Bigley JD, McBride D, Guo P, He D, Wang Z.

Prostate. 2019 Aug;79(11):1226-1237. doi: 10.1002/pros.23806. Epub 2019 Jun 18.

PMID:
31212363
12.

Change in Functional Status After Prostate Cancer Treatment Among Medicare Advantage Beneficiaries.

Jacobs BL, Lopa SH, Yabes JG, Nelson JB, Barnato AE, Degenholtz HB.

Urology. 2019 Sep;131:104-111. doi: 10.1016/j.urology.2019.05.029. Epub 2019 Jun 7.

PMID:
31181274
13.

Corrigendum to "A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles" [Virology 507 (2017) 242-256].

Meador LR, Kessans SA, Kilbourne J, Kibler KV, Pantaleo G, Esteban M, Blattman JN, Jacobs BL, Mor TS.

Virology. 2019 Aug;534. pii: S0042-6822(19)30139-4. doi: 10.1016/j.virol.2019.05.018. Epub 2019 Jun 6. No abstract available.

PMID:
31178060
14.

Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer.

Macleod LC, Yabes JG, Yu M, Fam MM, Hale NE, Turner RM 2nd, Lopa SH, Gingrich JR, Borza T, Skolarus TA, Davies BJ, Jacobs BL.

Urol Oncol. 2019 Jul;37(7):462-469. doi: 10.1016/j.urolonc.2019.04.006. Epub 2019 Apr 30.

PMID:
31053530
15.

Multiparametric Magnetic Resonance Imaging Is Associated with Increased Medicare Spending in Prostate Cancer Active Surveillance.

Macleod LC, Yabes JG, Fam MM, Bandari J, Yu M, Maganty A, Furlan A, Filson CP, Davies BJ, Jacobs BL.

Eur Urol Focus. 2019 Apr 25. pii: S2405-4569(19)30124-5. doi: 10.1016/j.euf.2019.04.008. [Epub ahead of print]

PMID:
31031042
16.

Downstream Studies Following the Use of Bone Scan in the Staging of Muscle-invasive Bladder Cancer.

Maganty A, Turner RM 2nd, Yabes JG, Davies BJ, Heron DE, Jacobs BL.

Urology. 2019 Jul;129:74-78. doi: 10.1016/j.urology.2019.04.009. Epub 2019 Apr 18.

PMID:
31005656
17.

Increasing Utilization of Multiparametric Magnetic Resonance Imaging in Prostate Cancer Active Surveillance.

Fam MM, Yabes JG, Macleod LC, Bandari J, Turner RM 2nd, Lopa SH, Furlan A, Filson CP, Davies BJ, Jacobs BL.

Urology. 2019 Aug;130:99-105. doi: 10.1016/j.urology.2019.02.037. Epub 2019 Mar 30.

PMID:
30940480
18.

Palliative care use amongst patients with bladder cancer.

Hugar LA, Lopa SH, Yabes JG, Yu JA, Turner RM 2nd, Fam MM, MacLeod LC, Davies BJ, Smith AB, Jacobs BL.

BJU Int. 2019 Jun;123(6):968-975. doi: 10.1111/bju.14708. Epub 2019 Mar 12.

PMID:
30758125
19.

Role of Post-Acute Care on Hospital Readmission After High-Risk Surgery.

Lee AJ, Liu X, Borza T, Qin Y, Li BY, Urish KL, Kirk PS, Gilbert S, Hollenbeck BK, Helm JE, Lavieri MS, Skolarus TA, Jacobs BL.

J Surg Res. 2019 Feb;234:116-122. doi: 10.1016/j.jss.2018.08.053. Epub 2018 Oct 6.

PMID:
30527462
20.

Small cell bladder cancer: should we consider prophylactic cranial irradiation?

Morgan TN, Turner RM II, Baptiste J, Lyon TD, Maranchie JK, Hrebinko RL, Davies BJ, Gingrich JR, Jacobs BL.

Int Braz J Urol. 2019 Mar-Apr;45(2):299-305. doi: 10.1590/S1677-5538.IBJU.2018.0242.

21.

The role of raptor in the mechanical load-induced regulation of mTOR signaling, protein synthesis, and skeletal muscle hypertrophy.

You JS, McNally RM, Jacobs BL, Privett RE, Gundermann DM, Lin KH, Steinert ND, Goodman CA, Hornberger TA.

FASEB J. 2019 Mar;33(3):4021-4034. doi: 10.1096/fj.201801653RR. Epub 2018 Dec 3.

PMID:
30509128
22.

Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.

Asbach B, Kibler KV, Köstler J, Perdiguero B, Yates NL, Stanfield-Oakley S, Tomaras GD, Kao SF, Foulds KE, Roederer M, Seaman MS, Montefiori DC, Parks R, Ferrari G, Forthal DN, Phogat S, Tartaglia J, Barnett SW, Self SG, Gottardo R, Cristillo AD, Weiss DE, Galmin L, Ding S, Heeney JL, Esteban M, Jacobs BL, Pantaleo G, Wagner R.

J Virol. 2019 Jan 17;93(3). pii: e01529-18. doi: 10.1128/JVI.01529-18. Print 2019 Feb 1.

23.

Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC.

Kibler KV, Asbach B, Perdiguero B, García-Arriaza J, Yates NL, Parks R, Stanfield-Oakley S, Ferrari G, Montefiori DC, Tomaras GD, Roederer M, Foulds KE, Forthal DN, Seaman MS, Self S, Gottardo R, Phogat S, Tartaglia J, Barnett S, Cristillo AD, Weiss D, Galmin L, Ding S, Heeney JL, Esteban M, Wagner R, Pantaleo G, Jacobs BL.

J Virol. 2019 Jan 17;93(3). pii: e01513-18. doi: 10.1128/JVI.01513-18. Print 2019 Feb 1. Erratum in: J Virol. 2019 Oct 15;93(21):.

24.

Rate and Determinants of Completing Neoadjuvant Chemotherapy in Medicare Beneficiaries With Bladder Cancer: A SEER-Medicare Analysis.

Hugar LA, Yabes JG, Turner RM 2nd, Fam MM, Appleman LJ, Davies BJ, Jacobs BL.

Urology. 2019 Feb;124:191-197. doi: 10.1016/j.urology.2018.11.001. Epub 2018 Nov 10.

PMID:
30423302
25.

Concentration of Opioid-Related Industry Payments in Opioid Crisis Areas.

Lee AJ, Bandari J, Macleod LC, Davies BJ, Jacobs BL.

J Gen Intern Med. 2019 Feb;34(2):187-189. doi: 10.1007/s11606-018-4700-7. No abstract available.

PMID:
30402818
26.

Extreme Price Variation for Generic Benign Prostatic Hyperplasia Medications.

Theisen KM, Park SY, Jeong K, Macleod LC, Bandari J, Ayyash O, Odisho AY, Jacobs BL, Davies BJ.

Urology. 2019 Feb;124:223-228. doi: 10.1016/j.urology.2018.10.020. Epub 2018 Oct 23.

PMID:
30359708
27.

Excessive Opioid Prescribing After Major Urologic Procedures.

Theisen KM, Myrga JM, Hale N, Cochran G, Sewall C, Macleod LC, Jacobs BL, Davies BJ.

Urology. 2019 Jan;123:101-107. doi: 10.1016/j.urology.2018.06.057. Epub 2018 Aug 24.

PMID:
30149041
28.

Effect of multimodal analgesia with paravertebral blocks on biochemical recurrence in men undergoing open radical prostatectomy.

Macleod LC, Turner RM 2nd, Lopa S, Hugar LA, Davies BJ, Ben-David B, Chelly JE, Jacobs BL, Nelson JB.

Urol Oncol. 2018 Aug;36(8):364.e9-364.e14. doi: 10.1016/j.urolonc.2018.05.016. Epub 2018 Jun 7.

PMID:
29887239
29.

Predictors and Cost of Readmission in Total Knee Arthroplasty.

Urish KL, Qin Y, Li BY, Borza T, Sessine M, Kirk P, Hollenbeck BK, Helm JE, Lavieri MS, Skolarus TA, Jacobs BL.

J Arthroplasty. 2018 Sep;33(9):2759-2763. doi: 10.1016/j.arth.2018.04.008. Epub 2018 Apr 17.

30.

The comparative effectiveness of quadratus lumborum blocks and paravertebral blocks in radical cystectomy patients.

Lee AJ, Yabes JG, Hale N, Hrebinko RL, Gingrich JR, Maranchie JK, Fam MM, Turner I I RM, Davies BJ, Ben-David B, Jacobs BL.

Can J Urol. 2018 Apr;25(2):9255-9261..

PMID:
29680003
31.

Prostate cancer chemoprevention by sulforaphane in a preclinical mouse model is associated with inhibition of fatty acid metabolism.

Singh KB, Kim SH, Hahm ER, Pore SK, Jacobs BL, Singh SV.

Carcinogenesis. 2018 May 28;39(6):826-837. doi: 10.1093/carcin/bgy051.

32.

Impact of Accountable Care Organizations on Diagnostic Testing for Prostate Cancer.

Luckenbaugh AN, Hollenbeck BK, Kaufman SR, Yan P, Herrel LA, Skolarus TA, Norton EC, Schroeck FR, Jacobs BL, Miller DC, Hollingsworth JM, Shahinian VB, Borza T.

Urology. 2018 Jun;116:68-75. doi: 10.1016/j.urology.2018.01.056. Epub 2018 Apr 6.

33.

Association Between Hospital Participation in Medicare Shared Savings Program Accountable Care Organizations and Readmission Following Major Surgery.

Borza T, Oerline MK, Skolarus TA, Norton EC, Dimick JB, Jacobs BL, Herrel LA, Ellimoottil C, Hollingsworth JM, Ryan AM, Miller DC, Shahinian VB, Hollenbeck BK.

Ann Surg. 2019 May;269(5):873-878. doi: 10.1097/SLA.0000000000002737.

PMID:
29557880
34.

Challenges in the Analysis of Outcomes for Surgical Compared to Radiotherapy Treatment of Prostate Cancer.

Glaser SM, Kalash R, Bongiorni DR, Roberts MS, Balasubramani GK, Jacobs BL, Beriwal S, Heron DE, Greenberger JS.

In Vivo. 2018 Jan-Feb;32(1):113-120.

35.

Evidence-Based Reporting: A Method to Optimize Prostate MRI Communications With Referring Physicians.

Magnetta MJ, Donovan AL, Jacobs BL, Davies BJ, Furlan A.

AJR Am J Roentgenol. 2018 Jan;210(1):108-112. doi: 10.2214/AJR.17.18260. Epub 2017 Nov 1.

PMID:
29091009
36.

Inhibition of DAI-dependent necroptosis by the Z-DNA binding domain of the vaccinia virus innate immune evasion protein, E3.

Koehler H, Cotsmire S, Langland J, Kibler KV, Kalman D, Upton JW, Mocarski ES, Jacobs BL.

Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):11506-11511. doi: 10.1073/pnas.1700999114. Epub 2017 Oct 9.

37.

Early effect of Medicare Shared Savings Program accountable care organization participation on prostate cancer care.

Borza T, Kaufman SR, Yan P, Herrel LA, Luckenbaugh AN, Miller DC, Skolarus TA, Jacobs BL, Hollingsworth JM, Norton EC, Shahinian VB, Hollenbeck BK.

Cancer. 2018 Feb 1;124(3):563-570. doi: 10.1002/cncr.31081. Epub 2017 Oct 20.

38.

The Comparative Effectiveness of Treatments for Ureteropelvic Junction Obstruction.

Jacobs BL, Lai JC, Seelam R, Hanley JM, Wolf JS Jr, Hollenbeck BK, Hollingsworth JM, Dick AW, Setodji CM, Saigal CS; Urologic Diseases in America Project.

Urology. 2018 Jan;111:72-77. doi: 10.1016/j.urology.2017.09.002. Epub 2017 Sep 21.

39.

Characterization of a PKR inhibitor from the pathogenic ranavirus, Ambystoma tigrinum virus, using a heterologous vaccinia virus system.

Huynh TP, Jancovich JK, Tripuraneni L, Heck MC, Langland JO, Jacobs BL.

Virology. 2017 Nov;511:290-299. doi: 10.1016/j.virol.2017.08.012. Epub 2017 Sep 14.

40.

Preoperative immunonutrition prior to radical cystectomy: a pilot study.

Lyon TD, Turner I I RM, McBride D, Wang L, Gingrich JR, Hrebinko RL, Jacobs BL, Davies BJ, Tarin TV.

Can J Urol. 2017 Aug;24(4):8895-8901.

PMID:
28832307
41.

Urologist Practice Affiliation and Intensity-modulated Radiation Therapy for Prostate Cancer in the Elderly.

Hollenbeck BK, Kaufman SR, Yan P, Herrel LA, Borza T, Schroeck FR, Jacobs BL, Skolarus TA, Shahinian VB.

Eur Urol. 2018 Apr;73(4):491-498. doi: 10.1016/j.eururo.2017.08.001. Epub 2017 Aug 18.

42.

Editorial Comment: Industry Payments to Urologists in 2014: an Analysis of the Open Payments Program.

Bandari J, Jacobs BL.

Urol Pract. 2017 Jul;4(4):347. No abstract available.

43.

The Fate of Radical Cystectomy Patients after Hospital Discharge: Understanding the Black Box of the Pre-readmission Interval.

Krishnan N, Li B, Jacobs BL, Ambani SN, Borza T, He C, Hollenbeck BK, Morgan T, Hafez KS, Weizer AZ, Montgomery JS, Lee CT, Lesse O, Lavieri MS, Helm JE, Skolarus TA.

Eur Urol Focus. 2018 Sep;4(5):711-717. doi: 10.1016/j.euf.2016.07.004. Epub 2016 Aug 4.

PMID:
28753778
44.

The lack of a relationship between physician payments from drug manufacturers and Medicare claims for abiraterone and enzalutamide.

Bandari J, Ayyash OM, Turner RM 2nd, Jacobs BL, Davies BJ.

Cancer. 2017 Nov 15;123(22):4356-4362. doi: 10.1002/cncr.30914. Epub 2017 Jul 27.

45.

Variation in readmission expenditures after high-risk surgery.

Jacobs BL, He C, Li BY, Helfand A, Krishnan N, Borza T, Ghaferi AA, Hollenbeck BK, Helm JE, Lavieri MS, Skolarus TA.

J Surg Res. 2017 Jun 1;213:60-68. doi: 10.1016/j.jss.2017.02.017. Epub 2017 Feb 23.

46.

A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles.

Meador LR, Kessans SA, Kilbourne J, Kibler KV, Pantaleo G, Roderiguez ME, Blattman JN, Jacobs BL, Mor TS.

Virology. 2017 Jul;507:242-256. doi: 10.1016/j.virol.2017.04.008. Epub 2017 Apr 28. Erratum in: Virology. 2019 Aug;534:.

47.

Comparative effectiveness in urology: a state of the art review utilizing a systematic approach.

Bandari J, Wessel CB, Jacobs BL.

Curr Opin Urol. 2017 Jul;27(4):380-394. doi: 10.1097/MOU.0000000000000405. Review.

PMID:
28426464
48.

Epidemiology of the Small Renal Mass and the Treatment Disconnect Phenomenon.

Turner RM 2nd, Morgan TM, Jacobs BL.

Urol Clin North Am. 2017 May;44(2):147-154. doi: 10.1016/j.ucl.2016.12.001. Epub 2017 Mar 14. Review.

49.

Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam Therapy.

Schroeck FR, Jacobs BL, Bhayani SB, Nguyen PL, Penson D, Hu J.

Eur Urol. 2017 Nov;72(5):712-735. doi: 10.1016/j.eururo.2017.03.028. Epub 2017 Mar 31. Review.

50.

The early adoption of intensity-modulated radiotherapy and stereotactic body radiation treatment among older Medicare beneficiaries with prostate cancer.

Jacobs BL, Yabes JG, Lopa SH, Heron DE, Chang CH, Schroeck FR, Bekelman JE, Kahn JM, Nelson JB, Barnato AE.

Cancer. 2017 Aug 1;123(15):2945-2954. doi: 10.1002/cncr.30574. Epub 2017 Mar 16.

Supplemental Content

Loading ...
Support Center